Stripe commits $500M to nonprofit Intercept in bid to eliminate respiratory viruses

Stripe, the payments infrastructure company, is putting $500 million behind a wildly ambitious idea: making respiratory viruses a thing of the past.

The new nonprofit, called Intercept, will initially target the common cold and influenza. Its long-term goal is nothing short of eradicating respiratory viruses entirely.

What Stripe is actually building

Patrick and John Collison, Stripe’s co-founders, are funding Intercept with the kind of money that turns theoretical science into actual labs and clinical trials. The $500 million commitment puts it in rare company among privately funded health initiatives.

For context, the common cold alone has stubbornly resisted every serious attempt at a cure for decades. There are over 200 viruses that can cause it, which is why your doctor’s best advice has always been some combination of rest, fluids, and hoping for the best.

Here’s the thing: this isn’t a startup chasing returns. It’s a nonprofit, which means the Collisons are structurally separating this effort from Stripe’s commercial operations.

Why a payments company cares about your cold

Patrick Collison co-founded the science-focused research organization Arc Institute, and both brothers have been vocal about what they see as underinvestment in basic scientific research.

Stripe itself has been on an acquisition and partnership tear that has nothing to do with respiratory medicine. The company acquired Bridge, a stablecoin-focused firm, in a deal valued at $1.1 billion. That acquisition was designed to deepen Stripe’s capabilities in the stablecoin infrastructure layer.

In January 2026, Stripe also announced a partnership with Crypto.com to enable cryptocurrency payments for its merchant base.

What this means for the broader landscape

Intercept doesn’t have a direct connection to Stripe’s crypto or payments business. No tokens are being launched. No blockchain-based health records are being pitched.

Stripe’s brand story now includes a health philanthropy chapter. For a company that already offers reduced payment processing rates to nonprofits, typically 2.2% plus $0.30 per transaction after verification, this creates a narrative coherence. Stripe processes payments for thousands of charitable organizations, and now it’s running one of the most ambitious nonprofits in the biomedical space.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.